Sarissa Capital Management LP 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-01-25 4:43 pm Purchase | 2021-01-15 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Sarissa Capital Management LP | 8,844,000 5.000% | 8,844,000 (New Position) | Filing |